9,10-Dioxoanthracenyldithiocarbamates effectively inhibit the proliferation of non-small cell lung cancer by targeting multiple protein tyrosine kinases
AbstractAnthraquinones have attracted considerable interest in the realm of cancer treatment owing to their potent anticancer properties. This study evaluates the potential of a series of new anthraquinone derivatives as anticancer agents for non-small-cell lung cancer (NSCLC). The compounds were su...
Saved in:
Main Authors: | Mateusz Olszewski (Author), Maryna Stasevych (Author), Viktor Zvarych (Author), Natalia Maciejewska (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016) -
Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017) -
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
by: Domenico Ribatti
Published: (2010) -
In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
by: Linda Wanika, et al.
Published: (2024) -
Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies
by: Made Putra Semadhi, et al.
Published: (2017)